177 related articles for article (PubMed ID: 34837103)
1. Efficacy and safety of
Yadav MP; Ballal S; Sahoo RK; Bal C
Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1595-1606. PubMed ID: 34837103
[TBL] [Abstract][Full Text] [Related]
2.
Parghane RV; Talole S; Basu S
Ann Nucl Med; 2021 Jan; 35(1):92-101. PubMed ID: 33135123
[TBL] [Abstract][Full Text] [Related]
3. Broadening horizons with
Ballal S; Yadav MP; Bal C; Sahoo RK; Tripathi M
Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):934-946. PubMed ID: 31707430
[TBL] [Abstract][Full Text] [Related]
4. Survival Outcomes in Metastatic Gastroenteropancreatic Neuroendocrine Tumor Patients receiving Concomitant
Ballal S; Yadav MP; Tripathi M; Sahoo RK; Bal C
J Nucl Med; 2022 Jul; ():. PubMed ID: 35863893
[No Abstract] [Full Text] [Related]
5. Efficacy and Safety of 225 Ac-DOTATATE in the Treatment of Neuroendocrine Neoplasms With High SSTR Expression.
Yang H; Zhang Y; Li H; Zhang Y; Feng Y; Yang X; Chen Y
Clin Nucl Med; 2024 Jun; 49(6):505-512. PubMed ID: 38498615
[TBL] [Abstract][Full Text] [Related]
6. Case Report: Primary Hypothyroidism Associated With Lutetium 177-DOTATATE Therapy for Metastatic Paraganglioma.
Gubbi S; Al-Jundi M; Del Rivero J; Jha A; Knue M; Zou J; Turkbey B; Carrasquillo JA; Lin E; Pacak K; Klubo-Gwiezdzinska J; Lin FI
Front Endocrinol (Lausanne); 2020; 11():587065. PubMed ID: 33551992
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcome of indigenous
Sitani K; Parghane RV; Talole S; Basu S
Br J Radiol; 2021 Jan; 94(1117):20201041. PubMed ID: 33095671
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcome of "Sandwich" chemo-PRRT: a novel treatment strategy for metastatic neuroendocrine tumors with both FDG- and SSTR-avid aggressive disease.
Parghane RV; Ostwal V; Ramaswamy A; Bhandare M; Chaudhari V; Talole S; Shrikhande SV; Basu S
Eur J Nucl Med Mol Imaging; 2021 Mar; 48(3):913-923. PubMed ID: 32876706
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of
Zidan L; Iravani A; Oleinikov K; Ben-Haim S; Gross DJ; Meirovitz A; Maimon O; Akhurst T; Michael M; Hicks RJ; Grozinsky-Glasberg S; Kong G
J Nucl Med; 2022 Feb; 63(2):218-225. PubMed ID: 34049983
[TBL] [Abstract][Full Text] [Related]
10. Initial Findings on the Use of [
Demirci E; Alan Selçuk N; Beydağı G; Ocak M; Toklu T; Akçay K; Kabasakal L
Mol Imaging Radionucl Ther; 2023 Oct; 32(3):226-232. PubMed ID: 37870290
[TBL] [Abstract][Full Text] [Related]
11. Peptide receptor radionuclide therapy with (177)Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and (18)F-FDG PET.
Ianniello A; Sansovini M; Severi S; Nicolini S; Grana CM; Massri K; Bongiovanni A; Antonuzzo L; Di Iorio V; Sarnelli A; Caroli P; Monti M; Scarpi E; Paganelli G
Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1040-6. PubMed ID: 26611427
[TBL] [Abstract][Full Text] [Related]
12. High clinical and morphologic response using
Kong G; Callahan J; Hofman MS; Pattison DA; Akhurst T; Michael M; Eu P; Hicks RJ
Eur J Nucl Med Mol Imaging; 2017 Mar; 44(3):476-489. PubMed ID: 27678267
[TBL] [Abstract][Full Text] [Related]
13. Metastatic Neuroendocrine Tumor with Extensive Bone Marrow Involvement at Diagnosis: Evaluation of Response and Hematological Toxicity Profile of PRRT with (177)Lu-DOTATATE.
Basu S; Ranade R; Thapa P
World J Nucl Med; 2016; 15(1):38-43. PubMed ID: 26912977
[TBL] [Abstract][Full Text] [Related]
14. 177Lu-DOTATATE PRRT in Patients with Metastatic Neuroendocrine Tumor and a Single Functioning Kidney: Tolerability and Effect on Renal Function.
Ranade R; Basu S
J Nucl Med Technol; 2016 Jun; 44(2):65-9. PubMed ID: 26848166
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based
Sundlöv A; Gleisner KS; Tennvall J; Ljungberg M; Warfvinge CF; Holgersson K; Hallqvist A; Bernhardt P; Svensson J
Eur J Nucl Med Mol Imaging; 2022 Sep; 49(11):3830-3840. PubMed ID: 35451612
[TBL] [Abstract][Full Text] [Related]
16. The efficacy of
Zhang J; Song Q; Cai L; Xie Y; Chen Y
J Cancer Res Clin Oncol; 2020 Jun; 146(6):1533-1543. PubMed ID: 32281025
[TBL] [Abstract][Full Text] [Related]
17. Concomitant
Yadav MP; Ballal S; Bal C
EJNMMI Res; 2019 Feb; 9(1):13. PubMed ID: 30725219
[TBL] [Abstract][Full Text] [Related]
18. Peptide Receptor Radionuclide Therapy Using
Kalantarhormozi M; Hassanzadeh S; Rekabpour SJ; Ravanbod MR; Jafari E; Amini A; Dadgar H; Mahmoudpour M; Nabipour I; Jokar N; Assadi M
World J Nucl Med; 2022 Sep; 21(3):215-221. PubMed ID: 36060085
[No Abstract] [Full Text] [Related]
19. Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLuS): a single-centre, single-arm, open-label, phase 2 study.
Braat AJAT; Bruijnen RCG; van Rooij R; Braat MNGJA; Wessels FJ; van Leeuwaarde RS; van Treijen MJC; de Herder WW; Hofland J; Tesselaar MET; de Jong HWAM; Lam MGEH
Lancet Oncol; 2020 Apr; 21(4):561-570. PubMed ID: 32112737
[TBL] [Abstract][Full Text] [Related]
20. Treatment of inoperable or metastatic paragangliomas and pheochromocytomas with peptide receptor radionuclide therapy using 177Lu-DOTATATE.
Zandee WT; Feelders RA; Smit Duijzentkunst DA; Hofland J; Metselaar RM; Oldenburg RA; van Linge A; Kam BLR; Teunissen JJM; Korpershoek E; Hendriks JM; Abusaris H; Slagter C; Franssen GJH; Brabander T; De Herder WW
Eur J Endocrinol; 2019 Jul; 181(1):45-53. PubMed ID: 31067510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
